NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

NCT05954910

RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Polatuzumab Vedotin

Countries: China

The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Be diagnosed as DLBCL
* Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment
* Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail
* Cohort 3: relapse or refractory to previous treatment

Exclusion Criteria:

* Participant who currently participates in or with plan to participate in any interventional clinical trial
* Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Locations (29)

Beijing, China
Beijing, China
Beijing, China
Beijing, China
Changchun, China
Changsha, China
Changsha, China
Chengdu, China
Guangzhou, China
Guiyang, China
Haikou, China
Hohhot, China
Nanchang, China
Nanjing, China
Nanjing, China
Qingdao, China
Shanghai, China
Shanghai, China
Shenyang, China
Shijiazhuang, China
Taiyuan, China
Tianjin, China
Tianjin, China
Ürümqi, China
Wuhan, China
Wuxi, China
Xi'an, China
Xuzhou, China
Zhengzhou, China